Who makes Lidocaine 2% Polyampoule?

Lidocaine 2% Polyampoule is developed by University of Alberta.

What development phase is Lidocaine 2% Polyampoule in?

Lidocaine 2% Polyampoule is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Lidocaine 2% Polyampoule

University of Alberta · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Lidocaine 2% Polyampoule
Also known as	No perturbation, Candy perturbation
Sponsor	University of Alberta
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Impact of Motor Tasks and Lidocaine on Reading Unfamiliar Words in Adults With and Without Dyslexia (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lidocaine 2% Polyampoule CI brief — competitive landscape report
Lidocaine 2% Polyampoule updates RSS · CI watch RSS
University of Alberta portfolio CI